Cargando…
The Proliferation REduction with Vascular ENergy Trial (PREVENT)
PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen sur...
Autores principales: | Raizner, Albert E, Kaluza, Grzegorz L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59647/ https://www.ncbi.nlm.nih.gov/pubmed/11806768 http://dx.doi.org/10.1186/cvm-2-1-016 |
Ejemplares similares
-
Cardiovascular Pharmacology: Contemporary Physiologic and Scientific Approaches to Cardiovascular Disease Prevention and Treatment
por: Young, James B., et al.
Publicado: (2022) -
Is it ‘cancer prevention’ or ‘risk reduction’? #Wordsmatter
por: Walker, Desiree A. H., et al.
Publicado: (2021) -
Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction
por: Vogel, Victor G
Publicado: (2015) -
Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus
por: Anstey, Kaarin J., et al.
Publicado: (2020) -
Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000)